Xstrahl provides UK healthcare professionals the ability to treat with Intraoperative Radiotherapy.
We are passionate about targeted cancer care expertly tailored to meet patients’ personalized needs. We carefully designed the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® to empower physicians with full confidence to precisely and effectively treat cancer and enable patients to live healthy, high-quality lives.
Xstrahl provides UK healthcare professionals and their patients the ability to treat with Intraoperative Radiotherapy (IORT) through the supply of Xoft Axxent systems and ORL (Oncotherapy Resources Ltd) mobile managed service.
For more information about Intraoperative Radiotherapy get in touch.
Oncotherapy Resources LTD
SD-IORT enables hospitals to offer patients ‘one dose, one treatment, one day’ radiotherapy option for early breast cancer employing cutting-edge technology, without the need for capital equipment purchase, maintenance costs or service charges, and at a low fee per patient (fully reimbursed by major insurers).
In the UK, breast cancer patients have benefited from ORL’s SD-IORT in several hospitals including Spire, Nuffield Health and BMI. ORL’s single dose radiotherapy treatment is expertly delivered at the point of surgery, offering patients a convenient and effective treatment experience. ORL utilises the Xoft® Axxent Electronic Brachytherapy System to deliver SD-IORT. The system is a simple-to-use, portable treatment device. Because the Xoft® Axxent System is mobile and requires minimal shielding, it can be used in local or regional hospitals, providing access to cutting-edge radiotherapy for breast cancer patients anywhere in the UK.
Intraoperative Radiotherapy (IORT) is a single dose of radiotherapy delivery at the time of breast conserving cancer surgery.
Xstrahl provides UK healthcare professionals and their patients the ability to treat with Intraoperative Radiotherapy. Take a look at Xstrahl 100, Xstrahl 150, Xstrahl 200 and Xstrahl 300 for other fast and effective treatments.
Here at Valley View, we have been using the Xstrahl 150 model to treat a high proportion of our patients with skin cancers and keloids for over 3 years now. When we were deciding which superficial radiotherapy unit to purchase, we were attracted to the Xstrahl models because they offered higher energies compared to competitor units. We also liked detailed features of the machine such as the water-cooling system and the interlock option on the filter selection. We love using the Xstrahl radiotheraphy system to treat our patients because of its user-friendly technology and variety of energy levels available. The system is very reliable and we have had 100% up time.
We have been using Xstrahl radiotherapy systems for 4 years and have successfully treated over 230 patients with this technology. We currently use the Xstrahl 100 machine and we find the system beneficial for treating basal cell and squamous cell carcinomas, as well as a wide range of other skin lesions and conditions. The Xstrahl system is easily transported between treatment rooms and has the added benefit of enabling us to effortlessly reconfigure our department layout.
I am so pleased that I chose SRT over reconstructive surgery. The treatment was very manageable. There was no “down time”. I continued my normal, daily schedule. The SRT was most successful as there is no evidence of treatment or basal cell on my nose now. I am so grateful SRT was an option.
The addition of an Xstrahl X-ray therapy system for treating superficial skin conditions such as non-melanoma skin cancer, will not only allow us to offer treatment to patient more effeciently, but also provide an enhanced patient experience. We are constantly striving to meet patient demand which is ever increasing and we are excited to have this option available to our patients.
Xstrahl radiotherapy systems help us to respond to a growing treatment demand, helping us to reduce surgical and hospitalisation costs. The team find the Xstrahl technology easy to use and helps them to deliver safe and effective radiotherapy to our patients.